Annexon (ANNX), Why Is The Market Paying Closer Attention?
Annexon (ANNX) is back in focus after a busy August, with a key update to its Phase 3 ARCHER II trial for vonaprument, fresh Guillain-Barré data, Q2 earnings, and a boardroom change drawing investor attention.
See our latest analysis for Annexon.
Over the past year Annexon has shifted from a relatively muted share price pattern to strong momentum, with a 12.79% year to date share price return and a very large 1 year total shareholder return of 116.80%, even though the 5 year total shareholder return remains down 68.42%. This suggests recent clinical updates, regulatory milestones and the Q2 loss profile are being interpreted as changing the balance between growth potential and risk.
If Annexon’s recent clinical news has your attention, it can also be useful to see what is happening in other health related opportunities, starting with 42 healthcare AI stocks.
For Annexon, the question now is whether the sharp swing in shareholder returns reflects a real shift in the clinical and regulatory profile, or whether sentiment has simply moved ahead of the fundamentals investors can value today.
Most Popular Narrative: 76.3% Overvalued
Annexon last closed at $5.29, while the most followed narrative places fair value at $3.00. That gap all hinges on how its lead programs play out.
Annexon’s use of a US$200 million credit facility and preparations for global commercialization increase fixed costs and financial leverage at a time when none of the key programs are approved. Any delay in regulatory decisions or slower than expected treatment uptake would leave interest expense and commercial infrastructure weighing on earnings and net margins.
Want to see what sits behind that cautious $3.00 figure? The narrative leans on sharp shifts in revenue, profit margins and a future earnings multiple that many investors usually associate with already scaled biotechs. Curious which assumptions need to hold together for that view to make sense.
Result: Fair Value of $3.00 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear swing factors for Annexon, including potential Guillain Barré approvals and positive vonaprument data in geographic atrophy that could challenge this cautious view.
Find out about the key risks to this Annexon narrative.
Another View on Annexon’s Valuation
The bearish narrative pegs Annexon’s fair value at $3.00, which implies the stock is overvalued. Our DCF model points in the opposite direction. It places fair value around $85.11, so at a share price of $5.29 the stock screens as very heavily undervalued. Which set of assumptions do you find more realistic?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Annexon for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment clearly split on Annexon, it makes sense to move quickly and look at the data first hand before forming a view. To weigh up the balance between potential rewards and the issues investors are worried about, start with the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Annexon?
If Annexon has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly compare fresh opportunities and keep your watchlist one step ahead.
- Target potential turnaround stories by checking out 20 elite penny stocks with strong financials that already show stronger balance sheets than many expect.
- Hunt for quality at a reasonable price with the 52 high quality undervalued stocks that combines solid fundamentals with attractive valuations.
- Prioritise resilience by scanning the 80 resilient stocks with low risk scores that highlights companies with steadier risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com